Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

The PCSK9 monoclonal antibody evolocumab (Repatha, Repatha Repatha Amgen) was well tolerated and effectively lowered LDL cholesterol by 38% compared with placebo in a randomized controlled trial in ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the risk of ...

Please provide your email address to receive an email when new articles are posted on . “We designed the EBBINGHAUS study ... to assess the following hypothesis: [Did] the addition of evolocumab to ...

Please provide your email address to receive an email when new articles are posted on . Confirming findings presented at recent scientific meetings, the PCSK9 inhibitor evolocumab was associated with ...

The addition of evolocumab to the standard background therapy for patients with atherosclerotic cardiovascular disease (ASCVD) would exceed the typically accepted range of cost-effectiveness, ...

The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to ...

Review the side-effects of Evolocumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

THOUSAND OAKS, CA — Treating statin-intolerant patients with evolocumab (Amgen, Thousand Oaks, CA) significantly lowers LDL-cholesterol levels, according to the top-line results of the GAUSS-2 study ...

Once again, two new analyses are calling into question the cost-effectiveness of adding the PCSK9 inhibitor evolocumab to statin therapy in patients with atherosclerotic cardiovascular disease, at ...

The PCSK9 inhibitor evolocumab (Repatha, Amgen) is far too expensive to make economic sense for the healthcare system and private payers, according to the results of yet another cost-effectiveness ...